<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702257</url>
  </required_header>
  <id_info>
    <org_study_id>7039</org_study_id>
    <nct_id>NCT03702257</nct_id>
  </id_info>
  <brief_title>DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection</brief_title>
  <official_title>Intérêt Diagnostique et Pronostique de la présence d'Anticorps spécifiques du Donneur Intra-greffon Dans le Rejet Humoral en Transplantation Pulmonaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of AMR in lung transplant recipients is difficult and often comes too late,
      because of lack of standardized definition. The diagnosis is nowadays based on an expert
      multidisciplinary approach involving clinical, histopathological and immunological criteria.

      Hypothesis: the presence of intragraft donor specific antibodies (gDSAs) could be used as a
      new diagnostic tool for AMR in lung transplant recipients Study Objectives: to evaluate, in
      lung transplant patients with circulating DSAs, the diagnostic value of gDSAs in AMR and to
      analyze its prognostic value on graft outcome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of AMR</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitivity and specificity of the presence of gDSA for the diagnosis of AMR in lung transplant recipients with circulating DSA, as established by an expert pathologist panel and in accordance with recent international recommendations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparaison in gDSA+ vs gDSAs- patients</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of graft loss</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Transplant Recipient</condition>
  <condition>Donor Specific Antibodies</condition>
  <condition>Antibody Mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Bronchial fibroscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bronchial fibroscopy with trans-bronchial biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchoscopy.</intervention_name>
    <description>gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.</description>
    <arm_group_label>Bronchial fibroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient older than 18 years

          -  Transplanted pulmonary or cardiopulmonary patient

          -  And developing circulating anti-HLA antibodies directed against the graft or &quot;DSA&quot; at
             a threshold &gt; 1000 of MFI in the 30 days preceding the inclusion visit

          -  Affiliation to the French social security

          -  Patient able to understand the objectives and risks related to research and to give
             informed, dated and signed consent

        Exclusion criteria:

        Pulmonary transplant patient already treated for humoral rejection (not to modify the
        histology)

          -  Patient whose anti-HLA antibodies are not directed against the graft (no DSA)

          -  Contraindication to performing a bronchial fibroscopy with transbronchial biopsies

          -  Treatment with intravenous immunoglobulin (less than 1 month before inclusion) or
             Rituximab (less than 6 months before inclusion)

          -  Plasma exchanges (less than 3 months before inclusion)

          -  Risk of bleeding predictable (crushing disorder, impossibility of stopping the
             offending treatments)

          -  Impossibility of giving the subject informed information

          -  Subject under the protection of justice Subject under guardianship or curatorship

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandrine HIRSCHI</last_name>
    <phone>+33 3 69 55 11 78</phone>
    <email>sandrine.hirschi@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme LE PAVEC</last_name>
      <phone>+33 1 40 94 24 30</phone>
      <email>lepavec@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martine REYNAUD GAUBERT</last_name>
      <phone>+33 1 40 25 82 37</phone>
      <email>martine.reynaud@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier BRUGIERE</last_name>
      <phone>+33 1 40 25 82 37</phone>
      <email>olivier.brugiere@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine HIRSCHI</last_name>
      <phone>+33 3 69 55 11 78</phone>
      <email>sandrine.hirschi@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine HIRSCHI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ROUX</last_name>
      <phone>+33 1 46 25 37 31</phone>
      <email>a.roux@hopital-foch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

